share_log

HC Wainwright & Co. Maintains Buy on Surface Oncology, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on Surface Oncology, Lowers Price Target to $6

HC Wainwright & Co.維持表面腫瘤學買入,將目標價下調至6美元
Benzinga Real-time News ·  2022/11/03 06:18

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Surface Oncology (NASDAQ:SURF) with a Buy and lowers the price target from $8.5 to $6.

HC Wainwright & Co. 分析師Swayampakula Ramakanth維持Surface Oncology(納斯達克股票代碼:SURF)的買入並將目標股價從8.5美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論